PaxMedica has engaged Bourne Partners

PaxMedica has engaged Bourne Partners, a leading financial services firm specializing in the pharma, pharma services, and consumer health sectors. This marks an important step in PaxMedica’s efforts to explore potential monetization of a Priority Review Voucher, PRV, prior to filing the NDA for PAX-101 for the treatment of African Sleeping Sickness. The engagement with Bourne Partners underscores PaxMedica’s commitment to optimizing its valuable assets to support the development of innovative healthcare solutions. Leveraging Bourne Partners’ extensive experience and network within the healthcare sector, PaxMedica aims to enhance its initiatives in the field of neurologic disorders and expedite critical research and development efforts. “We are excited to engage Bourne Partners to explore the structures that could potentially allow the company to monetize the value of a potential PRV,” stated Howard Weisman, Chairman and CEO of PaxMedica. “This represents our continued dedication to advancing healthcare solutions and underscores our commitment to driving meaningful change in the field of neurology.” PaxMedica anticipates qualifying for the PRV program as their treatment targets a rare, fatal tropical disease caused by a parasite currently listed by the FDA as eligible for the program. However, it’s important to note that PaxMedica has not been granted a PRV, and there is no guarantee that one will be awarded.